CSHP - California Society of Health-System Pharmacists

This week we are proud to spotlight Jackie Jaskowiak, CSHP Board Member, for her appointment as Vice Chair to the American Society of Health-System Pharmacists (ASHP) Section of Inpatient Care Practitioners (SICP) Advisory Group on Compounding Practice for 2024-2025!

Be sure to congratulate her on this amazing honor ➡️ https://bit.ly/3ydCiun

Check out our Weekly Seminar Session Spotlight!

Lead by Dr. Steven Kim and Dr. Esmaeil Sebti, this course will illustrate the expanding role and the integration of clinical pharmacy into neurology, focusing on a pharmacist-led ambulatory care clinic that manages patients with a history of stroke or transient ischemic attack (TIA) and uncontrolled risk factors.

The presentation will also discuss the structure and management of the interdisciplinary healthcare team through the Stroke Clinic, evaluates the value of the pharmacy team in optimal post-stroke care, and shares practical ideas and insight to expand neurology and cardiovascular pharmacy services.

Don't miss out on this session & more ➡️ https://www.cshp.org/Seminar2024

Free CE from Medscape: Navigating Relapsed/Refractory CLL/SLL Together: Where Disease-, Treatment-, and Patient-Centered Care Unite

Medscape will be hosting a free online CE activity exploring insights regarding relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This activity will help healthcare providers integrate evidence-based and patient-centered strategies for R/R CLL/small lymphocytic lymphoma (SLL) and consider how the treatment algorithm may evolve with novel targeted strategies.

Upon completing this activity, participants will be able to understand the recent clinical trial data on Bruton tyrosine kinase (BTK) inhibitors for the treatment of R/R CLL/SLL, recognize the factors that inform treatment decision-making for the individual patient with R/R CLL/SLL, create personalized treatment strategies for patients with R/R CLL/SLL, and apply effective communication strategies to individualize therapies based on needs and empower shared decision-making,

Pharmacists are a part of the target audience for this activity.

Valid for credit through 7/5/25
Registration is not required.
This event offers 1.25 contact hours in pharmacy education.

View the Medscape Activity information here:

Navigating Relapsed/Refractory CLL/SLL Together: Where Disease-, Treatment-, and Patient-Centered Care Unite Did you know 59% of patients value doctors asking about their information needs and desired level of care involvement? Join us to explore these and other insights in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Deadline Extended Through August 15 for the Student Leadership in Health-System Practice Award!

The CSHP Student Leadership in Health-System Practice Award recognizes students with an interest in health-system pharmacy practice who have demonstrated leadership ability.

This program recognizes and celebrates the contributions of a student who represent the very best attributes and accomplishments of CSHP student members in health-system practice.

Apply ➡️ https://www.cshp.org/SLHSPA

CDC Antimicrobial Resistance Threats in the United States, 2021-2022

The CDC recently provided an update on the burden of seven antimicrobial-resistant pathogens typically found in healthcare settings from 2021-2022 in the United States. The seven antimicrobial-resistant pathogens the new data follows were Carbapenem-resistant Enterobacterales (CRE), Carbapenem-resistant Acinetobacter, Candida auris (C. auris), Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE), Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, and Multidrug-resistant (MDR) Pseudomonas aeruginosa. Previously the CDC reported these pathogens increased in 2020 in the United States and the new data compares data from 2021 and 2022 to data from 2019.

The new data for the burden of six antimicrobial-resistant pathogens reveal a combined 20% increase during the COVID-19 pandemic compared to the pre-pandemic period. In 2022, the change in rates or number of infections for MRSA is stabilized compared to the increase for the six other pathogens. Antimicrobial resistance remains a public health threat in the United States and additional action needs to be done to combat antimicrobial resistance.

The CDC is implementing a new electronic reporting format in 2025 that will report on estimates for at least 19 antimicrobial resistance threats and an update on the U.S. burden of antimicrobial resistance. Once the new format is implemented, the CDC will release new estimates for the burden of these threats at least every two years.

View the CDC’s Antimicrobial Resistance Update here:

Antimicrobial Resistance Threats in the United States, 2021-2022 CDC used new data to update the U.S. burden of seven antimicrobial-resistant pathogens typically fou

𝙎𝙘𝙝𝙚𝙙𝙪𝙡𝙚 𝘼𝙣𝙣𝙤𝙪𝙣𝙘𝙚𝙙 𝙛𝙤𝙧 𝙎𝙚𝙢𝙞𝙣𝙖𝙧 2024

With three unique session tracks and over 70 educational sessions, we are excited for you to join us in Palm Springs!

View Schedule ➡️ https://www.cshp.org/S24_Schedule
Register ➡️ https://www.cshp.org/Seminar2024

3 Days Left to Submit Your Poster Abstract for Seminar 2024!

All residents, fellows, technicians, students, practitioners, and regional chapters are invited to share research and practice expertise in Palm Springs at Seminar 2024.

For more information and how to submit visit our website ➡️ https://www.cshp.org/S24_Posters

Free CE from Medscape and MMWR: Centers for Disease Control and Prevention Guidelines for the Prevention and Treatment of Anthrax, 2023

Medscape will be hosting a free online CE activity addressing updates to previous CDC guidelines and recommendations on preferred preventions and treatments in case of exposure to Bacillus anthracis. This activity will help healthcare professionals such as pharmacists prepare for possible crisis scenarios with anthrax.

Upon completing this activity, participants will be able to understand the epidemiology of anthrax in the United States and globally, distinguish preferred antibiotic regimens for postexposure prophylaxis against anthrax, evaluate recommended interventions following aerosol exposure to Bacillus anthracis, and analyze preferred therapy for the cases of systemic anthrax.

Pharmacists are a part of the target audience for this activity.

Valid for credit through 6/21/25
Registration is not required.
This event offers 1.25 contact hours in pharmacy education.

View the Medscape Activity information here:

Centers for Disease Control and Prevention Guidelines for the Prevention and Treatment of Anthrax, 2023 New guidelines help prepare healthcare professionals for possible crisis scenarios with anthrax.

Check out our University of the Pacific Student Chapter Newsletter!

Check out their student feature including their Roadmap to Residency: Learn Your Path session, CV Review Mock Residency Interview and much more ➡️ https://bit.ly/4f6g2mz

SAVE THE DATE for CSHP's 2025 Pharmacy Policy and Legislative Day!

Be sure to join us in Sacramento to advocate for the pharmacy profession in California.

· Earn CE’s as you learn about California’s legislative and regulatory landscapes.
· Discover the many ways CSHP has been advocating for pharmacy.
· Educate legislators on your profession.
· Network with colleagues & more!

Stay tuned for updates and details about what we have planned for 2025!

Last month, an article was published in the JAIDS Journal of Acquired Immune Deficiency Syndromes secondary to the work done with the California Pharmacist PEP & PrEP Survey.

CSHP would like to celebrate this publication and the two CSHP leaders involved with this article, Dr. Loriann De Martini and Dr. Jerika Lam.

This study evaluated the potential for LAI-PrEP provision in pharmacies through a mixed methods study of pharmacists in California, where Senate Bill 159 enables pharmacists to independently provide oral PrEP.

Read Full Publication ➡️ https://bit.ly/4bMoKUm

CDPH Recommends Students Complete Routine Vaccinations Ahead of New School Year

The California Department of Public Health (CDPH) reminds Californians with children in school to stay up to date on routine vaccinations and ensure their students receive the required recommended vaccinations before the new school year. It is required by California law for students enrolled in public and private elementary schools, secondary schools, and licensed childcare centers to receive age-specific immunizations before attending.

Vaccinations help protect against and prevent contagious diseases. Many preventable diseases such as the human papillomavirus (HPV) can lead to some forms of cancer if infected early on in life. HPV vaccination can help protect against HPV infection-related cancers. Children as young as 9 years ago are recommended to receive the HPV vaccine and schools in California are required to notify families of 6th graders about the HPV vaccine.

Families can check with the CDPH’s resource pages on the required immunizations to attend schools in California. Pharmacists in California can recommend, remind, and administer vaccines to students based on the CDC’s immunization schedules and as required by California law.

View the CDPH’s press release here:
https://www.cdph.ca.gov/Programs/OPA/Pages/NR24-017.aspx

View the CDPH’s Parents’ Guide to Required Immunizations:
https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Immunization/School/resources-parents.aspx

Today’s the day to make a difference.

We’re raising funds for the CSHP Foundation, and need your help — every dollar counts towards promoting health, wellness, and the optimal use of medication through research and education.

Donate today and join us in changing lives ➡️ https://www.cshp.org/Foundation_Donors

Free CE from Medscape and MMWR: Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023

Medscape will be hosting a free online CE activity addressing the new guidelines that focus on the best practices with the use of the tick-borne encephalitis (TBE) vaccine. This activity will help healthcare professionals such as pharmacists evaluate the clinical entity of TBE and its prevention through vaccination.

Upon completing this activity, participants will be able to understand the epidemiology and virology of TBE, evaluate the clinical presentation and laboratory diagnosis of patients with suspected TBE, assess the safety and immunogenicity of the TBE vaccine, and distinguish appropriate candidates for TBE vaccination.

Pharmacists are a part of the target audience for this activity.

Valid for credit through 6/21/25
Registration is not required.
This event offers 2.50 contact hours in pharmacy education.

View the Medscape Activity information here:
https://www.medscape.org/viewarticle/1001129

Are you a pharmacy student or resident getting ready to venture into the job market and want to know how your CV stacks up?

Join us at Seminar 2024 to have your resume reviewed 1:1 with a pharmacist or technician mentor to help you out with your future success!

Sign-up today ➡️ https://www.cshp.org/S24_CV_Review

ISMP: NAN Alert - Manufacturer’s DexmedeTOMIDine Premixed IV Bags May Be Packaged within An Overwrap Labeled as Acetaminophen

The Institute for Safe Medication Practices (ISMP) has published a National Alert Network (NAN) Alert warning healthcare providers of premixed IV bags packaged with an overwrap labeled for another medication.

The event was reported to ISMP that an infusion bag labeled with an overwrap of “acetaminophen 1,000 mg/100 mL'' was found to be “dexmedeTOMidine hydrochloride injection, 400 mcg/100 mL'' after the infusion was administered. The FDA and the manufacturer, Hikama, have been alerted of the concern, and a formal recall is planned.

Healthcare organizations with these products are recommended to check inventory and sequester products until further instruction. Organizations are to continue the best practice procedure of scanning the barcode directly on an infusion bag and not the overwrap as well as educate staff to be vigilant and pay attention to labels before scanning the barcode of Hikma’s acetaminophen injection.

View the ISMP NAN Alert here:
https://home.ecri.org/blogs/ismp-alerts-and-articles-library/manufacturer-s-dexmedetomidine-premixed-iv-bags-may-be-packaged-within-an-overwrap-labeled-as-acetaminophen

Are you seeking a mentor in pharmacy? Looking to mentee the next generation?

Look no further and take part in CSHP's New Practitioner Executive Committee's (NPEC) Mentorship Program for 2024-2025!

Sign up before the July 31st deadline ➡️ https://bit.ly/4f2yGft

This week we are proud to spotlight University of Southern California pharmacy student, Shannon Hang!

Hear from Shannon on the leadership role she tool on at the USC Student Chapter & Southern California Affiliate Chapter, experiences at Seminar and her advice to fellow colleagues ➡️ https://bit.ly/3zyof2W

Don't miss out on Early-bird Registration for Seminar 2024!

Savings of up to $200 ends on July 15th at 9PM PST so be sure to register and join us for the leading pharmacy conferences on the West Coast!

Learn more & register ➡️ https://www.cshp.org/Seminar2024

FDA Approves Treatment for Adults with Alzheimer’s Disease

The U.S. Food and Drug Administration (FDA) has approved an injection treatment for Alzheimer’s disease. Kisunla (donanemab-azbt) is an amyloid beta-directed antibody and is administered as an intravenous infusion every four weeks.

The FDA approved Kisunla (donanemab-azbt) to be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.
The dosage is 700 mg as an intravenous infusion administered over approximately 30 minutes every four weeks for the first three doses, followed by 1400 mg every four weeks.

The safety and efficacy of Kisunla (donanemab-azbt) were evaluated in a double-blind, placebo-controlled, parallel-group study (Study 1, NCT04437511) in patients with Alzheimer’s disease with confirmed presence of amyloid pathology and mild cognitive impairment or mild dementia stage of the disease. Precautions and warnings for Kisunla (donanemab-azbt) include a boxed warning for amyloid-related imaging abnormalities (ARIA). Patients who are ApoE ε4 homozygotes have a higher incidence of ARIA and should be tested for ApoE ε4 status before starting treatment. The most common side effects were ARIA, headache, and the risk of infusion-related reactions.

View the FDA’s announcement here:
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease

Free CE from Medscape and MMWR: Pre-Exposure Prophylaxis Among Transgender Women Without HIV Infection: US National Survey 2019-2020

Medscape will be hosting a free online CE activity addressing trends in the use of pre-exposure prophylaxis (PrEP) with current remaining challenges. This activity will help healthcare professionals such as pharmacists to be able to evaluate the use of PrEP among transgender women and variables associated with higher use of PrEP.

Upon completing this activity, participants will assess baseline trends in sexual behavior and transgender healthcare in the current cohort of transgender women, analyze the rates of discussion with healthcare providers regarding PrEP and use of PrEP among transgender women, and evaluate variables associated with increased PrEP use among transgender women and with decreased PrEP use among transgender women.

Pharmacists are a part of the target audience for this activity.

Valid for credit through 7/2/25
Registration is not required.
This event offers 0.50 contact hours in pharmacy education.

View the Medscape Activity information here:
https://www.medscape.org/viewarticle/1001219

Announcing our Preceptor Development CE Track at Seminar 2024!

As we look forward to our full schedule release we are excited to announce a part of our Preceptor Development track: When the Going gets Rough: Effective Coaching and Intervention Strategies with Learners in Difficulty!

Lead by Dr. Kathleen Besinque & Dr. Emmanuelle Schwartzman, this session will use case studies to focus on application of a systematic approach to identifying and addressing learner difficulties. Participants will also develop skills in mentoring, coaching, communication, and have the opportunity to practice specific strategies for working with challenging students.

Don't miss out on this session and more ➡️ https://www.cshp.org/Seminar2024

CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines

The CDC released its recommendations for the 2024-2025 Fall/Winter virus season. The CDC recommends those who are ages 6 months and older receive an updated 2024-2025 COVID-19 vaccine regardless of if they have ever previously been vaccinated with a COVID-19 vaccine. This recommendation will take effect as soon as the updated 2024-2025 COVID-19 vaccines become available later this year. The updated 2024-2025 COVID-19 vaccines will be provided by Moderna, Novavax, and Pfizer. Protection from COVID-19 vaccines declines over time and receiving the most updated COVID-19 vaccine will enhance protection against current circulating SARS-CoV-2 variants.

For influenza virus season, the CDC recommends those who are ages 6 months and older, with rare exceptions, receive an updated 2024-2025 flu vaccine. The updated 2024-2025 flu vaccines will all be trivalent and protect against an H1N1, H3N2, and a B/Victoria lineage virus. The CDC encourages providers to start their influenza vaccination planning efforts as soon as possible and to begin vaccinating patients once 2024-2025 influenza vaccines become available based on the following recommendations.

The CDC recommends the months of September and October as the best times for most people to get vaccinated for influenza. Vaccination from July to August is not recommended for most people, except for specific groups such as pregnant people who are in their third trimester and children who need two doses of the flu vaccine. Influenza vaccination should be considered for July to August for children with healthcare visits during that time, adults (especially those 65 years old and older), and pregnant people in the first and second trimesters if there may not be another opportunity for vaccination in September and October.

View the CDC’s news release here:
https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html

𝙍𝙚𝙡𝙖𝙭 & 𝙍𝙚𝙬𝙞𝙣𝙙 𝙖𝙩 𝙎𝙚𝙢𝙞𝙣𝙖𝙧 2024

Seminar is more than just education! At Seminar 2024 we will be bringing you a fun filled night of dancing, singing and a little gambling at the Agua Calient & Cascade Lounge!

Be sure to join us at Seminar for this amazing social event and more below!

Seminar Activities ➡️ https://www.cshp.org/S24_Excursions
Register ➡️ https://www.cshp.org/Seminar2024

Save & Register for Early Bird Discount prior to July 15th!

There is only 𝗢𝗡𝗘 𝗪𝗘𝗘𝗞 left to take advantage and save up to $200 on your Seminar 2024 registration!

To learn more and register visit our website at ➡️ https://www.cshp.org/Seminar2024

CDC COCA Call: Update on Highly Pathogenic Avian Influenza A(H5N1) Virus for Clinicians and Healthcare Centers

The CDC will host a COCA Call where presenters will discuss updates on the current outbreak in the United States, current CDC surveillance, and monitoring efforts for the Highly Pathogenic Avian Influenza (HPAI) (H5N1) virus. Highly Pathogenic Avian Influenza (HPAI) (H5N1) virus is that affects birds and in recent cases, has spillover to mammals, such as dairy cattle.

Though the risk is low to the public, those who have job-related or recreational exposure to infected birds or animals are at greater risk of HPAI A(H5N1) virus infection. To date, there have been three human cases of HPAI A(H5N1) virus infection identified in dairy farm workers in the United States.

The objectives of this COCA Call include understanding the epidemiology and clinical features of human cases of HPAI A(H5N1) virus infection, describing the risk of human infection with HPAI A(H5N1) viruses, and identifying the higher risk populations, and what to assess in clinical settings. Additionally, other objectives include describing testing, using antivirals, and infection prevention and control recommendations for patients with HPAI A(H5N1) virus infection.

Pharmacists are a part of the target audience for this call.

When: Tuesday, July 16, 2024, 11:00 AM - 12:00 PM PDT
Registration is not required.
The event offers 0.1 CEUs in pharmacy education.

View the COCA Call information here:
https://emergency.cdc.gov/coca/calls/2024/callinfo_071624.asp

We are happy to announce the launch of our annual New Practitioner Executive Committee's (NPEC) Mentorship Program for 2024-2025!

Interested in being a Mentor or Mentee? Sign up before the July 31st deadline ➡️ https://bit.ly/4f2yGft

CDC Updates Recommendations for RSV Vaccinations for Adults

The CDC has updated its recommendations for the use of the respiratory syncytial virus (RSV) vaccines in people ages 60 and older ahead of the upcoming respiratory virus season. Previously, the RSV vaccine was approved for those ages 60 and older. This 2024-2025 respiratory virus season, the CDC now recommends that people ages 75 and older receive the RSV vaccine. This recommendation is for those who have not received an RSV vaccine and did not get the RSV vaccine last year.

For those who are ages 60 to 74, the CDC recommends those who are at risk for severe RSV, which includes those with certain chronic medical conditions, such as lung or heart disease, or who live in nursing homes receive the RSV vaccine.

This updated recommendation is to simplify the RSV vaccine decision-making guidance for clinicians and the public. The RSV vaccine is not an annual vaccine and patients do not need to get a dose every respiratory season. The CDC recommends the best time to get vaccinated for RSV is in the late summer and early fall.

View the CDC’s announcement here:
https://www.cdc.gov/media/releases/2024/s-0626-vaccination-adults.html